Gilead Sciences, Inc. initiated two Phase III studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March. The initiation of these studies follows the U.S. FDA rapid review and acceptance of Gilead’s investigational new drug (IND) fil...